IO Biotech Ownership
| IOBT Stock | USD 0.92 0.04 4.55% |
IOBT |
IOBT Stock Ownership Analysis
About 67.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.79. Some equities with similar Price to Book (P/B) outperform the market in the long run. IO Biotech recorded a loss per share of 1.29. The entity had not issued any dividends in recent years. IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company was incorporated in 2014 and is based in Copenhagen, Denmark. Io Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 32 people. To learn more about IO Biotech call the company at 45 70 70 29 80 or check out https://www.iobiotech.com.Besides selling stocks to institutional investors, IO Biotech also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different IO Biotech's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align IO Biotech's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
IO Biotech Quarterly Liabilities And Stockholders Equity |
|
Less than 1% of IO Biotech are currently held by insiders. Unlike IO Biotech's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against IO Biotech's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of IO Biotech's insider trades
IOBT Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as IO Biotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading IO Biotech backward and forwards among themselves. IO Biotech's institutional investor refers to the entity that pools money to purchase IO Biotech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bridgeway Capital Management, Llc | 2024-12-31 | 174 K | Renaissance Technologies Corp | 2024-12-31 | 118.8 K | Sectoral Asset Management Inc | 2024-12-31 | 75 K | Royal Bank Of Canada | 2024-12-31 | 60 K | Ubs Group Ag | 2024-12-31 | 47 K | Geode Capital Management, Llc | 2024-12-31 | 33.3 K | Vontobel Holding Ltd. | 2024-12-31 | 32.7 K | Xtx Topco Ltd | 2024-12-31 | 28 K | Pks Advisory Services, Llc | 2024-12-31 | 16 K | Vivo Capital, Llc | 6.2 M | Novo A/s | 2024-12-31 | 3.4 M |
IO Biotech Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific IO Biotech insiders, such as employees or executives, is commonly permitted as long as it does not rely on IO Biotech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases IO Biotech insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
IO Biotech Outstanding Bonds
IO Biotech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. IO Biotech uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most IOBT bonds can be classified according to their maturity, which is the date when IO Biotech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for IOBT Stock Analysis
When running IO Biotech's price analysis, check to measure IO Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IO Biotech is operating at the current time. Most of IO Biotech's value examination focuses on studying past and present price action to predict the probability of IO Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IO Biotech's price. Additionally, you may evaluate how the addition of IO Biotech to your portfolios can decrease your overall portfolio volatility.